SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by SAB Biotherapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for SAB Biotherapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Kropotova Alexandra | CHIEF MEDICAL OFFICER | 41,853 | Sep 18, 2026 | 5 |
| Reich Samuel J | CEO | 219,001 | Feb 5, 2026 | 1 |
| Sullivan Eddie Joe | PRESIDENT | 5,232,304 | Feb 5, 2026 | 1 |
| Bausch Christoph Lawrence | CHIEF OPERATING OFFICER | – | Feb 5, 2026 | 1 |
| To Lucy | See Remarks | – | Feb 5, 2026 | 1 |
| Zaccardelli David | Director | – | Jan 7, 2026 | 1 |
| Jain Rita | Director | – | Jan 7, 2026 | 1 |
| Skyler Jay S | Director | – | Dec 18, 2025 | 1 |
| Lucera Erick | Director | – | Dec 18, 2025 | 1 |
| Polvino William James | Director | – | Dec 18, 2025 | 1 |
| Giberson Scott | Director | – | Dec 18, 2025 | 1 |
| Ellias Helen K. | Director | 2,857,142Indirect | Dec 18, 2025 | 1 |
| Link David | Director | – | Dec 18, 2025 | 1 |
| Sessa Capital IM, L.P. | Director | 2,198,457 | Oct 1, 2025 | 1 |
| Sessa Capital (Master), L.P. | Director | 2,198,457 | Oct 1, 2025 | 1 |
| Sessa Capital GP, LLC | Director | 2,198,457 | Oct 1, 2025 | 1 |
| Sessa Capital IM GP, LLC | Director | 2,198,457 | Oct 1, 2025 | 1 |
| Petry John | Director | 2,198,457 | Oct 1, 2025 | 1 |
| Moin Andrew | Director | 2,198,457Indirect | Oct 1, 2025 | 1 |
| Hamilton Christine E | Director | 3,111,334Indirect | Jul 17, 2024 | 0 |
| Spragens Jeffrey G | Director | 394,989 | Jul 17, 2024 | 0 |
| Link David Charles | Director | 57,313 | Jul 17, 2024 | 0 |
| King Michael | CHIEF FINANCIAL OFFICER | 5,000 | Feb 23, 2024 | 0 |
| Beyer Russell P | Chief Financial Officer | 15Indirect | Mar 16, 2023 | 0 |
| Finnegan Frederick | Chief Business Officer | 38,596 | Mar 18, 2022 | 0 |
| Pommer Jerry Lynn | Chief Compliance Officer | – | Mar 18, 2022 | 0 |
| Erickson Bruce Kipp | Chief Operating Officer | – | Mar 18, 2022 | 0 |
| Luke Thomas Charles | Chief Medical Officer | 5,428 | Mar 18, 2022 | 0 |
| Ullerich Melissa Vera | Chief Communications Officer | – | Mar 18, 2022 | 0 |
| Turner Mervyn | Director | – | Oct 26, 2021 | 0 |
| Wu Hua | SVP Research & Product Dev. | – | Oct 26, 2021 | 0 |
| Hamilton Edward D. | 10% Owner | 5,049,351Indirect | Oct 26, 2021 | 0 |
| Carillo Carlos N | SVP Regulatory Affairs | – | Oct 26, 2021 | 0 |
| Randall Charles Hiram | Chief Strategy Officer | – | Oct 26, 2021 | 0 |
| Katz Ilan | Director, 10% Owner | 1,500 | Oct 15, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 8, 2023 (view filing) | Dec 7 | 1 day | Sullivan Eddie JoeChief Executive Officer | PPurchase | +1.74K | $0.88 | +$1.53K | 0.0%5.23M after | |
| Nov 30, 2023 (view filing) | Nov 30 | Same day | King MichaelCHIEF FINANCIAL OFFICER | PPurchase | +5.00K | $0.90 | +$4.50K | New position5.00K after | |
| Nov 30, 2023 (view filing) | Nov 29 | 1 day | Reich Samuel JExecutive Chairman | PPurchase | +11.0K | $0.89 | +$9.79K | +5.3%219.0K after | |
| Sep 14, 2022 (view filing) | Sep 13 | 1 day | Hamilton Christine EDirector, 10% Owner | PPurchase | +10.0K | $0.73 | +$7.30K | +0.2%4.99M after | |
| Sep 8, 2022 (view filing) | Sep 7 | 1 day | Sullivan Eddie JoeCHIEF EXECUTIVE OFFICER | PPurchase | +14.0K | $0.74 | +$10.4K | +0.3%5.23M after | |
| Nov 16, 2021 (view filing) | Oct 26 | 21 daysLate | Beyer Russell PChief Financial Officer | SSale | −278 | $7.90 | −$2.20K | −100.0%0 after | |
| Oct 15, 2021 (view filing) | Oct 13 | 2 days | Katz IlanDirector, 10% Owner | PPurchase | +500 | $10.11 | +$5.05K | +50.0%1.50K after | |
| Oct 15, 2021 (view filing) | Oct 14 | 1 day | Reich Samuel JCEO and CFO | PPurchase | +1.00K | $10.11 | +$10.1K | New position1.00K after | |
| Oct 5, 2021 (view filing) | Oct 1 | 4 days | Spragens Jeffrey GDirector | PPurchase | +13.0K | $10.07 | +$130.9K | New position13.0K after | |
| Oct 5, 2021 (view filing) | Oct 1 | 4 days | Katz IlanDirector, 10% Owner | PPurchase | +1.00K | $10.09 | +$10.1K | New position1.00K after |